Summary & Overview
HCPCS J1201: Injection, Cetirizine Hydrochloride 0.5 mg
HCPCS Level II code J1201 denotes an injectable dose of cetirizine hydrochloride, 0.5 mg. The code is used when cetirizine is administered by injection in outpatient settings and is relevant to clinicians, billing staff, and payers managing allergy and antihistamine therapies. Nationally, injectable antihistamine billing impacts outpatient medication costs and reimbursement workflows for allergy, urgent care, and primary care services.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of what J1201 represents clinically and operationally, payer coverage context, and typical sites of service. The publication provides benchmarks for billing and utilization where available, summarizes relevant policy and coverage considerations, and situates J1201 within clinical practice for antihistamine therapy.
This summary addresses clinical context, billing implications, and practical coding considerations for revenue cycle and clinical teams working with injectable cetirizine.
Billing Code Overview
HCPCS Level II code J1201 represents an injection of cetirizine hydrochloride, 0.5 mg. This billing code covers administration of a low-dose injectable antihistamine formulation of cetirizine for therapeutic use.
-
Service type: Medication administration (injectable antihistamine)
-
Typical site of service: Ambulatory care settings such as outpatient clinics, physician offices, urgent care centers, and infusion suites where injectable medications are administered.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 6–12 year old child or an adult with severe allergic rhinitis or urticaria who presents to an outpatient infusion clinic or physician office for administration of injectable cetirizine hydrochloride (J1201, 0.5 mg). The clinical workflow begins with triage and allergy assessment by a nurse, verification of the order by the clinician, informed consent and allergy safety screening, preparation of the single-dose injectable product, and verification of patient identity and weight. The injection is administered intramuscularly or subcutaneously per product directions, with a 15–30 minute post-administration observation period for potential hypersensitivity or local injection reactions. Documentation includes the medication name and dose (cetirizine hydrochloride 0.5 mg), lot number, NDC if recorded, route, site of injection, start and end times, and any immediate adverse events. Billing uses HCPCS Level II code J1201 for the administered drug; applicable modifier(s) are appended per payer and clinical circumstances. Typical sites of service are outpatient infusion centers, physician offices (allergy, pediatrics, family medicine, otolaryngology), urgent care clinics, and emergency departments for acute reactions.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |